Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Novo Nordisk stock rose after good news from the FDA on Wegovy—it’s popular weight-loss drug which has the same active ...

T elemedicine company GoodRx ( GDRX) has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new ...

Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a ...

Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy ...

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

The Ozempic price cut could appease US President Donald Trump, who has pushed for drug companies to lower their prices.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.